Kybernin P

Antithrombin III, the active ingredient in Kybernin P, is a antithrombin presented as an injection for intravenous use. It is employed to correct antithrombin deficiency and to augment heparin anticoagulation in patients at risk of thrombosis.

GNH USA supplies Kybernin P as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Kybernin P is an antithrombin concentrate used in the management of disorders that affect the coagulation cascade.

- Congenital antithrombin deficiency: restores antithrombin activity to reduce thrombotic risk. - Heparin resistance: enhances heparin efficacy when standard dosing fails to achieve target anticoagulation. - Cardiopulmonary bypass surgery: provides anticoagulation support during extracorporeal circulation. - Liver transplantation: maintains adequate anticoagulation in patients with low antithrombin levels.

Kybernin P may be associated with adverse reactions following intravenous administration.

Common Side Effects: - Infusion‑related fever or chills. - Headache or mild dizziness. - Nausea or abdominal discomfort. - Transient hypotension during infusion.

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions. - Unexpected bleeding or hemorrhage. - Thrombotic events despite therapy. - Hemolysis or severe hematuria. - Sepsis related to contaminated product.

When using Kybernin P, clinicians should observe several safety considerations.

- Monitor antithrombin activity: check plasma levels before and during therapy. - Assess bleeding risk: evaluate patient history of hemorrhage or coagulopathy. - Use caution with concurrent anticoagulants: adjust dosing to avoid over‑anticoagulation. - Avoid in active uncontrolled bleeding: defer administration until bleeding is managed. - Verify product integrity: inspect for particulate matter or discoloration before infusion. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kybernin P can interact with other agents that affect haemostasis.

Major Interactions (Avoid): - Concurrent use with other anticoagulants (e.g., direct thrombin inhibitors, factor Xa inhibitors): may cause excessive bleeding. - High‑dose heparin combined with antithrombin concentrate without monitoring: risk of over‑anticoagulation.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs) or antiplatelet agents: increase bleeding tendency. - Thrombolytic therapy (e.g., alteplase): may augment hemorrhagic risk. - Certain antibiotics (e.g., aminoglycosides) that affect renal clearance: monitor antithrombin levels.